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Background: Studies investigating the association between Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections
and intrahepatic cholangiocarcinoma (ICC) have reported inconsistent findings. We conducted a meta-analysis of
epidemiological studies to explore this relationship.
Methods: A comprehensive search was conducted to identify the eligible studies of hepatitis infections and ICC risk up
to September 2011. Summary odds ratios (OR) with their 95% confidence intervals (95% CI) were calculated with
random-effects models using Review Manager version 5.0.
Results: Thirteen case–control studies and 3 cohort studies were included in the final analysis. The combined risk
estimate of all studies showed statistically significant increased risk of ICC incidence with HBV and HCV infection
(OR=3.17, 95% CI, 1.88-5.34, and OR=3.42, 95% CI, 1.96-5.99, respectively). For case–control studies alone, the combined
OR of infection with HBV and HCV were 2.86 (95% CI, 1.60-5.11) and 3.63 (95% CI, 1.86-7.05), respectively, and for cohort
studies alone, the OR of HBV and HCV infection were 5.39 (95% CI, 2.34-12.44) and 2.60 (95% CI, 1.36-4.97), respectively.
Conclusions: This study suggests that both HBV and HCV infection are associated with an increased risk of ICC.Background
Intrahepatic cholangiocarcinoma (ICC), which originates
from intrahepatic bile ducts, is the second commonest
primary hepatic tumour behind hepatocellular carcin-
oma (HCC), accounting for 3% of all gastrointestinal
cancers worldwide [1]. The etiology of ICC is poorly
understood although several etiological factors, including
hepatolithiasis [2], primary sclerosing cholangitis [3],
liver flukes (Clonorchis sinensis and Opisthorchis viver-
rini) [4] and exposure to the radiopaque medium thor-
ium dioxide (Thorotrast) [5], has been well established.
It has been shown that Hepatitis B virus (HBV) and
hepatitis C virus (HCV) infections are the major causa-
tive agent for HCC [6]. Several recent studies have been* Correspondence: yjm.1952@yahoo.com.cn; hejia63@yahoo.com
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reproduction in any medium, provided the orconducted to investigate the association of ICC with
viral hepatitis infections, but the conclusions remained
controversial [7-15]. For example, a case–control study
from Korea found neither HBV nor HCV infection was
associated with the risk of ICC [7]. In contrast, a case–
control study from Italy found that seropositivities for
anti-HCV and hepatitis B surface antigen (HBsAg) were
25% and 13% in ICC cases and 5.8% and 6.7% in con-
trols, respectively. A statistically significant increase in the
odds ratios (OR) was observed for anti-HCV (OR=9.7),
whereas no significant association was found with HBsAg
(OR=2.7) [8]. On the other hand, the results of a case–
control study from China showed a positive association of
ICC with HBV but not with HCV [9]. Therefore, we con-
ducted a meta-analysis to address the inconsistent results
reported in previous studies, thereby improving the esti-
mate of ICC risk in HBV- or HCV- infected patients.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Literature flow chart.
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Study selection
To identify the relevant literature, searches of PubMed,
Embase, Ovid, Cochrane Library, and Scopus database
for articles on ICC associated with HBV or HCV infec-
tion were conducted up to September 2011. The following
MeSH (Medical Subject Heading) search headings were
used: ‘hepatitis B virus’,” “hepatitis C virus,” “bile duct neo-
plasms”, and “cholangiocarcinoma”. Reference lists of all
retrieved articles were manually searched for additional
studies. Serum HBsAg and hepatitis C antibody were
used as the positive markers of chronic hepatitis virus
infection.
Criteria for inclusion and exclusion
The inclusion criteria in the meta-analysis are as follows:
published full-text report in English language, studies
provided sufficient data to calculate the risk estimates
with its corresponding 95% confidence interval (CI) of
ICC associated with HBV or HCV infection.
Abstracts, letters, editorials and expert opinions,
reviews without original data, case reports and studies
lacking control groups were excluded. The following
studies were also excluded: 1) those evaluating patients
with HCC or liver metastase; 2) those with incomplete
raw data; 3) those with repetitive data.
Data extraction
Two reviewers (B.L. and Y.Z.) independently extracted
the following parameters from published studies: the
name of the first author, publication year, study design,
the country in which the study was conducted, sample
size, prevalence of HBV or HCV seropositivity in cases
and in a control group or in cohort, and OR or hazard
ratios (HR) estimates with 95% CI for HBV or HCV in-
fection and ICC.
Quality assessment
The methodological quality of the included studies
assessed using a three-items scoring system measured by
the study design (cohort =1; case–control =0), sample
size (>100 =1; 100 = 0), and reported outcomes of inter-
est (both HBV and HCV =1; HBV or HCV only = 0).
Studies having a score of 2 were considered to be of high
quality.
Statistical methods
The literature review refered to PRISMA statement stan-
dards.We extracted adjusted OR and HR with 95% CI
from the included studies. Summary OR was estimated
using random-effects models. Heterogeneity was calcu-
lated by means of Q test and χ2 test. Publication bias
was assessed visually using a funnel plot. All analyseswere conducted using Review Manager (RevMan) soft-
ware 5.0.Results
Selection of studies
Figure 1 shows the flow chart of publications identified
by the literature search. A total of 13 case–control studies
[7-19] and 3 cohort studies [20-22] were included in the
meta-analysis. The main features of the studies included
in the meta-analysis are shown in Tables 1 and 2. Among
the 13 case–control studies, three were from United States
[10,11,15], three from China [9,18,19], three from Korea
[7,14,16], one from Italy [8], one from Thailand [13], one
from Taiwan [17], and one from Japan [12]. Control sub-
jects originated from hospital-based [7-9,11-14,16-19], or
general population-based population [10,15].
Among the 3 cohort studies, one was from United
States [20], one from Japan [21], and one from Taiwan
[22]. The average observation period ranged from 2.3 to
7.6 years.
The two reviewers had 100% agreement in their
reviews of the data extraction.
Table 1 Characteristics of case–control studies of hepatitis viruses infection and ICC risk




Control description OR (95% CI) for
HBV infection




Parkin 1991 Thailand 100 100 Hospital-based control 1.0 (0.4-2.1) – 1
Shin 1996 Korea 41 406 Hospital-based control 1.3 (0.3-5.3) 3.9 (0.9-17.1) 2
Donato 2001 Italy 26 824 Hospital-based control 2.7 (0.4-18.5) 9.7 (1.6-58.9) 2
Yamamoto 2004 Japan 50 205 Hospital-based control 1.8 (0.3-10.1) 16.8 (5.7-50.0) 2
Shaib 2005 US 625 90834 Population-based control 0.8 (0.1-5.9) 6.1 (4.3-8.6) 2
Choi 2006 Korea 185 185 Hospital-based control 0.8 (0.198-3.023) 1.0(0.04-25.264) 2
Shaib 2007 US 83 236 Hospital-based control 2.9 (0.1-236.8) 7.9 (1.3-84.5) 2
Welzel 2007 US 535 102782 Population based control – 4.4 (1.4-14.0) 1
Lee 2008 Korea 622 2488 Hospital-based control 2.3 (1.6-3.3) 1.0 (0.5-1.9) 2
Zhou 2008 China 312 438 Hospital-based control 8.876 (5.98-13.19) 0.933 (0.281-3.1) 2
Lee 2009 Taiwan 160 160 Hospital-based control 4.985 (2.78-8.95) 2.71 (1.16-6.32) 2
Tao 2010 China 61 380 Hospital-based control 18.1 (7.5-44.0) – 1
Peng 2011 China 98 196 Hospital-based control 2.75 (1.27-5.95) – 1
ICC, intrahepatic cholangiocarcinoma; HBV,hepatitis B virus; HCV, hepatitis C virus; US, United States.
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Meta-analysis of all these 16 studies in a random-effects
model found statistically significant increased risk of
ICC incidence with HBV and HCV infection (OR=3.17,
95% CI, 1.88-5.34, P< 0.001 and OR= 3.42, 95% CI,1.96-
5.99, P< 0.001, respectively). When case–control studies
were analyzed alone, the combined OR for the association
of HBV and HCV infection with the risk for ICC were
2.86 (95% CI, 1.60-5.11) and 3.63 (95% CI, 1.86-7.05), re-
spectively. When cohort studies were analyzed alone, the
combined OR of HBV and HCV infection were 5.39 (95%
CI, 2.34-12.44) and 2.60 (95% CI, 1.36-4.97), respect-
ively. All these results were significant heterogeneous
(P< 0.001) (Figures 2 and 3).Sensitivity analysis of high quality studies
Analysis of these studies [7-12,14,16,17,20-22] revealed
both HBV (OR=3.10, 95% CI, 1.77-5.42, P< 0.001) and
HCV infection (OR=3.35, 95% CI, 1.82-6.15, P< 0.001)
were associated with significant increased risk of ICC
development.Table 2 Characteristics of cohort studies of hepatitis viruses i
First author Year Country Source Sample size
Tanaka 2009 Japan Voluntary blood donors 2519 (HBsAg +)
1927 (anti-HCV+)
150368 (all negative
El-Serag 2009 US Veterans population 146394 (anti-HCV+)
572293 (anti-HCV–)
Fwu 2011 Taiwan Pregnant women 289992 (HBsAg +)
1492409 (HBsAg –)
ICC, intrahepatic cholangiocarcinoma; HBsAg, hepatitis B surface antigen; HCV, hepaPublication bias
A “funnel plot” of the studies in the meta-analysis report-
ing HBV infection and ICC is shown in Figure 4. Five of
the studies lay outside the 95% confidence interval bound-
aries, and significant heterogeneity was observed.Discussion
Meta-analysis was employed by a recently published study
to estimate the correlation between hepatitis virus infection
and the risk of ICC and extrahepatic cholangiocarcinoma
(ECC) [23]. Because different anatomic location of CC has
distinct epidemiologic features indicating different sets of
risk factors [11], here we used meta-analysis to examine the
relationship between HBV/HCV infection and the risks of
ICC, and restricted our analysis to patients only with ICC.
In this meta-analysis, we found positive relationship
between HBV/HCV infection and the development of
ICC. This conclusion is further supported by the evi-
dences from a series of experimental studies. In a study
from the United States, HBV and/or HCV DNA was
present in 3 (27%) out of 11 ICC tissue samples obtainednfection and ICC risk
Mean follow-up (years) ICC Hazard ratio 95% CI Study ,quality
7.6 2 8.56 (1.33-55.2) 3
1 2.63 (.25-27.73)
) 8
2.3 14 2.6 (1.3-5.0) 2
23
6.91 9 4.80 (1.88-12.2) 2
9
titis C virus; US, United States.
Figure 2 Forest plot of intrahepatic cholangiocarcinoma risk associated with HBV infection.
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from China also showed that HBV DNA was detected in
34.8% (8/23) of ICC cases [25]. Recently, Torbenson
et al. [26] found that dysplasia of the intrahepatic bileFigure 3 Forest plot of intrahepatic cholangiocarcinoma risk associatducts, the histologic precursor lesion of ICC, was
present in HCV related cirrhotic livers.
The mechanism of the development of ICC in patients
with HBV or HCV infection is still uncertain. HBV anded with HCV infection.
Figure 4 Funnel plot of studies evaluating the association between HBV infection and intrahepatic cholangiocarcinoma risk.
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liver. Indeed, chronic inflammation and cancer are
closely associated. In this context, long-term expression
of several viral oncoproteins, mostly the HCV core pro-
tein and HBx protein, might participate in the tumouri-
genic process. Battaglia et al. [27] found that HCC
derived-HCV core variants alleviate TGF-beta cytostatic
responses and increase TGF-beta-mediated epithelial to
mesenchymal transition (EMT) in mouse or human pri-
mary hepatocytes. Interestingly, Li et al. [28] reported
that HCV core protein expression can induce EMT in
cholangiocarcinoma cell line. On the other hand, HBx
acting as a transactivator on various cellular genes that
are involved in the control of the cell cycle, proliferation
or apoptosis has been shown to be present in some
HBV-infected ICC specimens [29]. There are reports
providing evidence that HBx gene transfection can upre-
gulate the transcriptional expression of human telomer-
ase reverse transcriptase mRNA both in HCC and
cholangiocarcinoma cell lines [30]. Clinically, Peng et al.
[19] reported that ICC patients with HBV infection were
more common in male and younger patients as com-
pared to ICC patients with seronegative HBsAg, similar
to HCC patients. Furthermore, the profile of age distri-
bution of ICC patients with HBV infection was roughly
close to that of HCC patients. Similarly, Lee et al. [17]
also found that both viral hepatitis-associated ICC and
HCC had similar age profiles and difference in age dis-
tributions between patients with chronic hepatitis B and
patients with chronic hepatitis C. In addition, the surgi-
cal outcomes of ICC patients with hepatitis, preopera-
tively diagnosed as HCC, is favorable, similar to that of
typical HCC patients [31]. Taking these clinical and ex-
perimental findings into account, it seems to bereasonable that hepatitis virus–associated ICC and HCC
share common disease processes for carcinogenesis.
Some researchers suggest that hepatocytes and cholan-
giocytes might originate from hepatic progenitor cells
(HPCs) [32]. Therefore it is possible that both ICC and
HCC in patients infected with HBV and HCV may be
derived from HPCs. In fact, cumulative studies have pro-
vided strong evidence to this hypothesis. Cumulative evi-
dence suggests that HBV- and HCV-associated HCC
and ICC are derived from HPCs. (i) It has been demon-
strated that HPCs can be infected with HBV and HCV,
and that proliferation of large numbers of HPCs was
seen in HBV- and HCV-associated cirrhosis which is a
risk factor for liver cancer [33,34]. (ii) Based on gross
morphological features, ICC are classifiable into three
representative types of growth patterns: the mass-
forming (MF) type, the periductal infiltrating (PI) type,
and the intraductal growth (IG) type [35]. It is likely that
PI and IG type tumors arise from malignant transform-
ation of epithelial cells lining the larger bile ducts,
whereas the MF type arises from smaller bile ducts or
liver progenitor cells within portal areas [36]. Yamamoto
et al. [37] speculated that HCV-infected proliferating
cholangioles in patients with chronic hepatitis C might
be associated with the development of MF type ICC. Yu
et al. [36] found that viral hepatitis-associated ICC was
more likely to be of the MF type rather than the PI and
IG type. (iii) Alpha-fetoprotein (AFP) is a marker of
HPCs compartments [38]. Viral hepatitis-associated ICC
patients were found had elevated serum alpha-fetoprotein
levels as compared with seronegative ICC patients [19,36].
One possible mechanism for the development of ICC is
that the neoplastic transformation of HPCs is involved in
the genesis of ICC and that the HPCs retain their ability
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formation [38]. Indeed, Ishii et al. [39] demonstrated that
AFP-producing cells in cholangiocarcinomas possessed
cancer stem cell-like properties. More importantly, one
most recent study from China found that HBx induces in-
trinsic cellular transformation, promoting the expansion
and tumorigenicity of HPCs in 3,5-diethoxycarbonyl- 1,
4-dihydrocollidine treated mice [40].
ICC is characterized by wide variability in incidence
and risk factors. HCV seems to be associated with ICC
in regions with relatively low prevalence of HBV infec-
tion such as United States, Italy and Japan. In contrast,
several studies from China [9,18,19], a highly endemic
area for HBV infection, found that not HCV but HBV
infection was significantly associated with ICC. On the
other hand, a recent study from Taiwan, where both
HBV and ICC are endemic, found that both HBV and
HCV are significantly associated with ICC [17]. These
studies indicate that the different endemic hepatitis virus
types in different regions may be a determinant to the
variability of risk factors for ICC.
Our study also has some weaknesses which should be
considered when interpreting results. First, seropositivity
for HBsAg and anti-HCV was used as the sole indicator
of HBV and HCV infection. It seems that occult HBV
and HCV infection may also play a role in the develop-
ment of HCC [41]. Therefore, the definition in the
present report might result in underestimation of the ef-
fect of hepatitis viruses infection. Second, there were sig-
nificant heterogeneities between different studies, which
would lower the reliability of the summary odds ratio.
The presence of heterogeneity is most likely to have
been introduced by diversity in study design, population
demographics, location of studies conducted and adjust-
ments for confounders. Finally, the possibility of publica-
tion bias is of concern. The fact that studies with
positive results are more likely to be published than
negative and non-English studies were excluded in the
current meta-analysis might be sources of potential pub-
lication bias.Conclusions
In conclusion, in this meta-analysis of 13 case–control
studies and 3 cohorts, we found that HBV and HCV in-
fection are associated with an increased risk of ICC.Competing interests
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